MarketPeel
Insider Trading Intelligence
Pricing
…
KW

Kory James Wentworth

TRDA
CHIEF FINANCIAL OFFICER · ENTRADA THERAPEUTICS, INC. · CIK 0001725663
FILING MIX · LIFETIME35%/65%
BUYS
38
SELLS
70
TOTAL VALUE
$2.15M
COMPANIES
1
ACTIVE SINCE
Oct 2021
HOLDINGS NOW
119,010
AVG SELL PX
$14.12
TRADE KIND
SHOWING 108 / 108
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
35 backtested trades · 8 horizons · 20 pending
Forward-return performance of every backtestable P/S trade by Kory James Wentworth, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d35+48.57%+0.30%-0.83%+1.12%-1.62%0.66
14d35+42.86%+0.72%-1.69%+2.41%+3.66%1.07
30d35+31.43%+2.49%-2.34%+4.83%+8.64%1.73
60d35+45.71%+0.99%-0.69%+3.11%+6.58%0.56
90d35+54.29%-7.88%+2.27%-9.11%-4.34%-1.65
180d35(4 pending)+74.19%-11.62%+6.12%-17.74%-18.82%-3.17
1y35(5 pending)+40.00%-2.92%+16.68%-19.60%-17.00%-3.52
2y35(11 pending)+33.33%-3.87%+44.11%-47.98%-38.84%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TRDA · 119,010 shares · as of Apr 1, 2026
038,65777,313115,970154,62620222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 38 buys / 70 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,500$12.95$32.4K119,010Apr 1, 2026Apr 2, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,388$13.02$148.2K121,510Mar 10, 2026Mar 11, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,089$13.00$66.2K132,898Mar 9, 2026Mar 11, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,988$12.25$97.9K137,987Mar 4, 2026Mar 6, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
5,712$11.76$67.2K145,975Mar 3, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,939$11.66$34.3K151,687Mar 2, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
44,600——154,626Mar 1, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
66,600——66,600Mar 1, 2026Mar 3, 2026 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,910$9.98$88.9K110,026Nov 21, 2025Nov 24, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,734$5.43$9.4K118,936Sep 2, 2025Sep 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
11,134$2.10$23.4K120,670Apr 3, 2025Apr 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
11,134——20,023Apr 3, 2025Apr 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,784$10.67$19.0K109,536Mar 17, 2025Mar 19, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,929$11.68$57.6K111,320Mar 3, 2025Mar 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
42,400——116,249Mar 1, 2025Mar 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
63,300——63,300Mar 1, 2025Mar 4, 2025 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
5,000——31,157Dec 2, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
5,000$2.10$10.5K78,849Dec 2, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,000$20.00$100.0K73,849Dec 2, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,000$2.10$2.1K74,849Nov 29, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,000——36,157Nov 29, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,000$19.97$20.0K73,849Nov 29, 2024Dec 3, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,637$19.98$172.6K73,849Nov 11, 2024Nov 13, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
6,000$2.10$12.6K82,486Nov 11, 2024Nov 13, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
6,000——37,157Nov 11, 2024Nov 13, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,195$14.97$47.8K76,486Sep 9, 2024Sep 10, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
165$15.13$2.5K79,681Sep 5, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
941$15.42$14.5K79,846Sep 4, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
462$15.76$7.3K80,950Sep 3, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
14$17.70$24880,787Sep 3, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
149$16.93$2.5K80,801Sep 3, 2024Sep 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,758$14.95$26.3K81,412Jul 8, 2024Jul 10, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
9,000$2.10$18.9K83,170Mar 15, 2024Mar 19, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
9,000——43,157Mar 15, 2024Mar 19, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,086$12.31$50.3K74,170Mar 6, 2024Mar 8, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,471$12.28$18.1K78,256Mar 5, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
405$13.37$5.4K79,727Mar 4, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
339$12.42$4.2K80,132Mar 4, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,900——80,471Mar 1, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
46,800——46,800Mar 1, 2024Mar 5, 2024 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
94——52,157Dec 26, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
94$16.67$1.6K49,571Dec 26, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
94$2.10$19749,665Dec 26, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
10,206$2.10$21.4K59,777Dec 22, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,529$15.24$99.5K53,248Dec 22, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
10,206——52,251Dec 22, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,677$16.48$60.6K49,571Dec 22, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,200——62,457Dec 21, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
2,200$2.10$4.6K51,771Dec 21, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,200$15.07$33.2K49,571Dec 21, 2023Dec 26, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
46$14.03$64549,571Sep 6, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
904$13.45$12.2K49,617Sep 6, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
426$14.46$6.2K50,521Sep 5, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,500——21,500Sep 1, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,200——50,947Sep 1, 2023Sep 6, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
8,790$2.10$18.5K36,747Jun 29, 2023Jun 30, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
8,790——74,657Jun 29, 2023Jun 30, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,907$15.17$135.1K27,957Jun 21, 2023Jun 23, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,593$14.84$127.5K36,864Jun 21, 2023Jun 23, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
17,500——83,447Jun 21, 2023Jun 23, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
17,500$2.10$36.8K45,457Jun 21, 2023Jun 23, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,602$10.46$16.8K42,302Mar 2, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,005$11.60$11.7K43,904Mar 2, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
145$11.23$1.6K42,157Mar 2, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,400——44,909Mar 1, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
43,000——43,000Mar 1, 2023Mar 3, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,200——27,957Mar 1, 2023Apr 19, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,500——21,500Mar 1, 2023Apr 19, 2023 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,550$18.95$86.2K16,509Dec 8, 2022Dec 12, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,550——100,947Dec 8, 2022Dec 12, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
4,550$2.10$9.6K21,059Dec 8, 2022Dec 12, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200——105,497Dec 5, 2022Dec 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
200$2.10$42016,709Dec 5, 2022Dec 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200$18.05$3.6K16,509Dec 5, 2022Dec 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
2,910$2.10$6.1K19,419Dec 2, 2022Dec 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,910$18.20$52.9K16,509Dec 2, 2022Dec 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,910——105,697Dec 2, 2022Dec 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200——108,607Nov 16, 2022Nov 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
200$2.10$42016,709Nov 16, 2022Nov 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200$18.10$3.6K16,509Nov 16, 2022Nov 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,503——16,489Sep 1, 2022Sep 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,551$14.18$22.0K10,986Aug 25, 2022Aug 26, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,117——108,807Aug 24, 2022Aug 26, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
301$14.23$4.3K12,537Aug 24, 2022Aug 26, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,817$13.52$38.1K12,838Aug 24, 2022Aug 26, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,117$2.10$2.3K15,655Aug 24, 2022Aug 26, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,909$13.09$38.1K14,538Aug 23, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
1,403$2.10$2.9K17,447Aug 23, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,403——109,924Aug 23, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
117$2.10$24616,261Aug 22, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
217$13.00$2.8K16,044Aug 22, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
117——111,327Aug 22, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
8,529$13.08$111.5K16,144Aug 19, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
4,452——111,444Aug 19, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
4,452$2.10$9.3K24,673Aug 19, 2022Aug 23, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200$13.00$2.6K20,221Aug 18, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
100$2.10$21020,441Aug 18, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
100——115,896Aug 18, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
100$2.10$21020,541Aug 17, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
100——115,996Aug 17, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200$13.07$2.6K20,341Aug 17, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
100——116,096Aug 16, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
SALE
Chief Financial Officer
200$13.00$2.6K20,441Aug 16, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
100$2.10$21020,641Aug 16, 2022Aug 18, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
33,019——33,019Jul 1, 2022Jul 6, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
66,038——66,038Mar 1, 2022Mar 3, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,006——20,541Mar 1, 2022Mar 3, 2022 ↗View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,012——72,012Oct 28, 2021Nov 1, 2021 ↗View →
Other insiders · TRDA
Loading peer insiders…
About this filer
CIK 0001725663
ROLE
Chief Financial Officer
PRIMARY
TRDA
COMPANIES
1
ACTIVE SINCE
Oct 2021
MARKETPEEL · /INSIDER/0001725663DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback